[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Jiangsu vcare pharmaceutical technology co., LTD\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":201},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,40,59,82,99,121,139,160,180],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100640383","phase-3-phase-iii-clinical-study-of-vc005-in-adult-and-adolescents-with-mild-to-moderate-atopic-dermatitis-100640383",false,"NCT07592585","Phase III Clinical Study of VC005 in Adult and Adolescents With Mild to Moderate Atopic Dermatitis","Phase III Clinical Study to Evaluate the Efficacy and Safety of VC005 in Adult and Adolescents With Mild to Moderate Atopic Dermatitis","Inclusion Criteria:\n\n1. Subjects fully understand this study, are able to follow the relevant procedures of the trial, voluntarily participate in the clinical trial, and sign the informed consent form (ICF);\n2. The age requirement for signing the ICF is 12 years old or above, with no gender restrictions;\n3. During screening, the diagnosis of atopic dermatitis should be met according to the Hanifin-Rajka criteria.\n\nExclusion Criteria:\n\n1. Patients whose AD course is judged by the investigator as unstable(spontaneous improvement or rapid worsening) within 2 weeks prior to baseline;\n2. At screening and baseline, lesions are localized only to the hands or feet, with no prior history of involvement of other typical areas (such as the face or flexural areas);\n3. Skin damage or abnormalities that may affect the evaluation of the investigational drug administration site (e.g., pigmentation, extensive scarring, tattoos, etc., at the affected area);\n4. At screening and baseline, presence of skin diseases that may affect the evaluation of the administration site, including but not limited to: psoriasis, acne, skin cancer, generalized erythroderma, Netherton syndrome, etc.","ALL","12 Years",{"count":19,"type":20},360,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","A multicenter, randomized, double-blind, vehicle controlled phase III clinical study to evaluate the efficacy and safety of VC005 in adults and adolescents with mild to moderate atopic dermatitis",[26],"Atopic Dermatitis","NOT_YET_RECRUITING","2026-05-18",{"date":30,"type":31},"2026-05-20","ACTUAL",{"date":33,"type":20},"2026-05-30",{"date":35,"type":20},"2028-05-30",{"name":37,"class":38},"Jiangsu vcare pharmaceutical technology co., LTD","INDUSTRY",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":44,"acronym":4,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":16,"minAge":46,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":21,"phases":49,"briefSummary":51,"conditions":52,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":55,"completionDateStruct":56,"leadSponsor":58,"locationsCount":39},"100640312","phase-2-a-multicenter-randomized-double-blind-vehicle-controlled-phase-ii-clinical-study-to-evaluate-the-efficacy-and-safety-of-vc005-gel-in-adult-subjects-with-mild-to-moderate-atopic-dermatitis-100640312","NCT07598383","A Multicenter, Randomized, Double-blind, Vehicle Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of VC005 Gel in Adult Subjects With Mild to Moderate Atopic Dermatitis","Inclusion Criteria:\n\n1. Subjects fully understand this study, are able to follow the relevant procedures of the trial, voluntarily participate in the clinical trial, and sign the informed consent form (ICF);\n2. The age requirement for signing the ICF is 18 years old or above, with no gender restrictions;\n3. During screening, the diagnosis of atopic dermatitis should be met according to the Hanifin-Rajka criteria.\n\nExclusion Criteria:\n\n1. Patients judged by the investigator to have an unstable course of Atopic Dermatitis (AD) (spontaneous improvement or rapid deterioration) within 2 weeks before baseline;\n2. Patients with skin lesions limited to the hands or feet at screening and baseline, with no prior history of involvement in other typical areas (such as the face or flexural folds);\n3. Skin damage or abnormalities that may affect the evaluation of the investigational drug administration site (e.g., hyperpigmentation, large-area scars, tattoos, etc. at the affected site);\n4. Presence of skin diseases at screening and baseline that may affect the evaluation of the administration site, including but not limited to: psoriasis, acne, skin cancer, generalized erythroderma, Netherton's syndrome, etc.;\n5. Patients with a history of malignant tumors, with the exception of: cervical carcinoma in situ, non-metastatic cutaneous squamous cell carcinoma or basal cell carcinoma, or non-metastatic papillary thyroid carcinoma that have been completely resected with no evidence of recurrence for more than 5 years of survival.","18 Years",{"count":48,"type":20},120,[50],"PHASE2","This is a multicenter, randomized, double-blind, vehicle controlled phase II clinical study to evaluate the efficacy and safety of VC005 gel in adult subjects with mild to moderate atopic dermatitis",[26],"2026-05-14",{"date":30,"type":31},{"date":33,"type":20},{"date":57,"type":20},"2027-02-22",{"name":37,"class":38},{"id":60,"slug":61,"hasResults":11,"nctId":62,"briefTitle":63,"officialTitle":63,"acronym":4,"eligibilityCriteria":64,"healthyVolunteers":65,"sex":16,"minAge":46,"maxAge":66,"enrollmentInfo":67,"targetDuration":4,"studyType":21,"phases":69,"briefSummary":71,"conditions":72,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":39},"100635352","phase-1-pharmacokinetics-of-vc005-tablets-in-subjects-with-renal-impairment-and-normal-renal-function-100635352","NCT07551570","Pharmacokinetics of VC005 Tablets in Subjects With Renal Impairment and Normal Renal Function","Inclusion Criteria:\n\n1. Voluntarily sign the informed consent form prior to the trial, fully understand the trial content, procedures, and possible adverse reactions, and be able to complete the study in accordance with the protocol requirements;\n2. Participants (including their partners) are willing to have no pregnancy plan from screening until 3 months after the last study drug administration and voluntarily take effective contraceptive measures; and have no plans to donate sperm or eggs;\n3. Male and female participants aged 18 to 70 years (inclusive);\n4. Male participants weighing no less than 50.0 kg, female participants weighing no less than 45.0 kg. Body mass index (BMI) between 18 and 32 kg\u002Fm² (inclusive).\n\nExclusion Criteria:\n\n1. History of allergies, including to drugs, food, dust mites, etc., known allergy to the study drug or any of its components;\n2. History of drug abuse, drug addiction and\u002For alcohol abuse (consumption of 14 units of alcohol per week: 1 unit = 285 mL beer, or 25 mL spirits, or 100 mL wine); positive results in drug abuse screening and alcohol screening;\n3. Blood donation or significant blood loss (\\> 400 mL) within 3 months prior to screening; or plan to donate blood during the trial;\n4. Average daily smoking of more than 5 cigarettes within 3 months prior to screening; or inability to stop using any tobacco products during the trial;\n5. History of recurrent herpes zoster, disseminated herpes zoster, or disseminated herpes simplex;\n6. Known active bacterial, viral, fungal, parasitic infection or other infection, or any infectious event requiring antibiotic treatment or hospitalization (within 4 weeks prior to screening), or any acute infection within 2 weeks of baseline;\n7. History of dysphagia or, within 6 months prior to screening, any gastrointestinal conditions affecting drug absorption or excretion (e.g., reflux esophagitis, peptic ulcer, chronic diarrhea, chronic constipation), history of liver disease (regardless of cure), and history of surgery (e.g., gastrointestinal surgery and other major surgeries).",true,"70 Years",{"count":68,"type":20},32,[70],"PHASE1","This study is a Phase I, single-dose, open-label trial designed to evaluate the pharmacokinetics and safety of a single oral dose of 25 mg VC005 tablets in participants with renal impairment compared to participants with normal renal function.",[73],"Renal Impairment","2026-04-20",{"date":76,"type":31},"2026-04-27",{"date":78,"type":20},"2026-04-30",{"date":80,"type":20},"2026-10-30",{"name":37,"class":38},{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":86,"acronym":4,"eligibilityCriteria":87,"healthyVolunteers":65,"sex":16,"minAge":46,"maxAge":88,"enrollmentInfo":89,"targetDuration":4,"studyType":21,"phases":91,"briefSummary":92,"conditions":93,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":95,"startDateStruct":96,"completionDateStruct":97,"leadSponsor":98,"locationsCount":39},"100635351","phase-1-pharmacokinetics-of-vc005-tablets-in-subjects-with-hepatic-impairment-and-normal-hepatic-function-100635351","NCT07551557","Pharmacokinetics of VC005 Tablets in Subjects With Hepatic Impairment and Normal Hepatic Function","Inclusion Criteria:\n\n1. Voluntarily sign the informed consent form prior to the trial, fully understand the trial content, procedures, and possible adverse reactions, and be able to complete the study in accordance with the protocol requirements;\n2. Participants (including their partners) are willing to have no pregnancy plan from screening until 3 months after the last study drug administration and voluntarily take effective contraceptive measures; and have no plans to donate sperm or eggs;\n3. Male and female participants aged 18 to 79 years (inclusive);\n4. Male participants weighing no less than 50.0 kg, female participants weighing no less than 45.0 kg. Body mass index (BMI) between 18 and 32 kg\u002Fm² (inclusive).\n\nExclusion Criteria:\n\n1. History of allergies, including to drugs, food, dust mites, etc., known allergy to the study drug or any of its components;\n2. History of drug abuse, drug addiction and\u002For alcohol abuse (consumption of 14 units of alcohol per week: 1 unit = 285 mL beer, or 25 mL spirits, or 100 mL wine); positive results in drug abuse screening and alcohol screening;\n3. Blood donation or significant blood loss (\\> 400 mL) within 3 months prior to screening; or plan to donate blood during the trial; or use of albumin within 14 days before the first dose of the study drug;\n4. Average daily smoking of more than 5 cigarettes within 3 months prior to screening; or inability to stop using any tobacco products during the trial;\n5. History of recurrent herpes zoster, disseminated herpes zoster, or disseminated herpes simplex;\n6. Known active bacterial, viral, fungal, parasitic infection or other infection, or any infectious event requiring antibiotic treatment or hospitalization (within 4 weeks prior to screening), or any acute infection within 2 weeks of baseline;\n7. History of dysphagia or, within 6 months prior to screening, any gastrointestinal conditions affecting drug absorption or excretion (e.g., reflux esophagitis, peptic ulcer, chronic diarrhea, chronic constipation), history of renal disease (confirmed renal disease regardless of cure; if only laboratory abnormalities such as elevated creatinine, hematuria, etc., to be assessed by the investigator), and history of surgery (e.g., gastrointestinal surgery and other major surgeries).","79 Years",{"count":90,"type":20},24,[70],"This study is a Phase I, single-dose, open-label trial designed to evaluate the pharmacokinetics and safety of a single oral dose of 25 mg VC005 tablets in participants with mild and moderate hepatic impairment compared to participants with normal hepatic function.",[94],"Hepatic Impairment and Healthy Female",{"date":76,"type":31},{"date":78,"type":20},{"date":80,"type":20},{"name":37,"class":38},{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":4,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":16,"minAge":46,"maxAge":66,"enrollmentInfo":106,"targetDuration":4,"studyType":21,"phases":108,"briefSummary":109,"conditions":110,"keywords":4,"overallStatus":112,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":39},"100606192","phase-3-efficacy-and-safety-phase-iii-clinical-study-of-vc005-tablets-in-subjects-with-active-ankylosing-spondylitis-100606192","NCT07172360","Efficacy and Safety Phase III Clinical Study of VC005 Tablets in Subjects With Active Ankylosing Spondylitis.","A Multicenter, Randomized, Double-blind, Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of VC005 Tablets in Subjects With Active Ankylosing Spondylitis","Inclusion Criteria:\n\n* The subject understands and voluntarily signs the informed consent form (ICF) and is willing and able to comply with the study protocol;\n* The subject is between 18 and 70 years of age (including borderline values) at the time of signing the ICF, regardless of gender;\n* The subject has been diagnosed with AS according to the 1984 New York Revised Criteria for Ankylosing Spondylitis\n\nExclusion Criteria:\n\n* Those who may be allergic to VC005, similar drugs or their excipients.\n* Individuals who have undergone organ transplantation in the past and require continuous use of immunosuppressants.\n* Those who, for any reason, are considered by the investigator to be unsuitable for participation in this study.",{"count":107,"type":20},420,[23],"This clinical trial is a multicenter, randomized, double-blind, controlled phase III clinical study.",[111],"Active Ankylosing Spondylitis","RECRUITING","2025-12-29",{"date":115,"type":31},"2026-01-02",{"date":117,"type":31},"2025-12-26",{"date":119,"type":20},"2027-08-30",{"name":37,"class":38},{"id":122,"slug":123,"hasResults":11,"nctId":124,"briefTitle":125,"officialTitle":126,"acronym":4,"eligibilityCriteria":127,"healthyVolunteers":11,"sex":16,"minAge":46,"maxAge":128,"enrollmentInfo":129,"targetDuration":4,"studyType":21,"phases":130,"briefSummary":131,"conditions":132,"keywords":4,"overallStatus":112,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":134,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":138,"locationsCount":39},"100606191","phase-2-efficacy-and-safety-phase-ii-study-of-vc005-tablets-in-subjects-with-non-segmental-vitiligo-100606191","NCT07172347","Efficacy and Safety Phase II Study of VC005 Tablets in Subjects With Non-segmental Vitiligo","A Multicenter, Randomized, Double-blind, Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of VC005 Tablets in Subjects With Non-segmental Vitiligo","Inclusion Criteria:\n\n* The subject understands and voluntarily signs the informed consent form (ICF) and is willing and able to comply with the study protocol.\n* The subject is between 18 and 70 years of age (including borderline values) , regardless of gender.\n\nExclusion Criteria:\n\n* Pregnant or lactating women, or subjects with pregnancy or lactation plans during the study period.\n* All hair in the vitiligo area on the face is white.\n* Those who are known or suspected to be allergic to the main ingredients and excipients of VC005 or similar drugs.\n* Subjects who have previously received depigmentation treatment.\n* Subjects who have received experimental drug administration or participated in device clinical trials within the first month or 5 half lives (whichever is longer) prior to randomization.","75 Years",{"count":48,"type":20},[50],"This clinical trial is a multicenter, randomized, double-blind, controlled phase II clinical study",[133],"Non-segmental Vitiligo",{"date":115,"type":31},{"date":136,"type":31},"2025-10-31",{"date":119,"type":20},{"name":37,"class":38},{"id":140,"slug":141,"hasResults":11,"nctId":142,"briefTitle":143,"officialTitle":144,"acronym":4,"eligibilityCriteria":145,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":146,"targetDuration":4,"studyType":21,"phases":148,"briefSummary":149,"conditions":150,"keywords":4,"overallStatus":112,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":153,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":159,"locationsCount":39},"100566682","phase-3-phase-iii-clinical-study-of-vc004-in-patients-with-localized-advanced-metastatic-solid-tumors-100566682","NCT06658353","Phase III Clinical Study of VC004 in Patients With Localized Advanced\u002F Metastatic Solid Tumors","Single-arm, Open, Multi-center Phase III Clinical Study to Assess the Safety and Effectiveness of VC004 in Patients With Localized Advanced\u002F Metastatic Solid Tumors","Inclusion Criteria:\n\n* All subjects or legal representatives are willing and able to sign ICF approved by the ethics committee before starting any screening procedures；\n* Male or female, age ≥12 years old;\n\nExclusion Criteria:\n\n* Patients have undergone major surgery within 4 weeks prior to the first dose or are expected to undergo major surgery during the trial (excluding vascular access establishment procedures, biopsy procedures);\n* Adverse reactions caused by previous treatment have not recovered to ≤1 grade (evaluated by the investigator);\n* Patients had been treated with a strong CYP3A inhibitor or inducer within 7 days prior to the first administration of the study drug.",{"count":147,"type":20},54,[23],"This Study is a single arm, open label, multicenter phase III clinical trial to evaluate the safety and efficacy of VC004 in patients with locally advanced\u002Fmetastatic solid tumors.",[151],"Locally Advanced Solid Tumor","2025-03-18",{"date":154,"type":31},"2025-03-20",{"date":156,"type":31},"2025-03-17",{"date":158,"type":20},"2026-12-30",{"name":37,"class":38},{"id":161,"slug":162,"hasResults":11,"nctId":163,"briefTitle":164,"officialTitle":165,"acronym":4,"eligibilityCriteria":166,"healthyVolunteers":11,"sex":16,"minAge":46,"maxAge":128,"enrollmentInfo":167,"targetDuration":4,"studyType":21,"phases":169,"briefSummary":170,"conditions":171,"keywords":4,"overallStatus":112,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":179,"locationsCount":39},"100571655","phase-3-phase-iii-clinical-study-of-vc005-tablets-in-adult-patients-with-moderate-to-severe-atopic-dermatitis-100571655","NCT06723080","Phase III Clinical Study of VC005 Tablets in Adult Patients With Moderate to Severe Atopic Dermatitis","A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of VC005 Tablets in Adult Patients With Moderate to Severe Atopic Dermatitis","Inclusion Criteria:\n\n(1）The patient understands and voluntarily signs the Informed Consent Form (ICF), and has the willingness and ability to complete the regular visits,treatment plans, laboratory tests and other experimental procedures required by the program. (2) Male or female patients aged ≥18 and ≤75 years at the time of signing the ICF. (3) Meet Hanifin-Rajka diagnostic criteria at screening and have atopic dermatitis （AD) symptoms for at least 1 year prior to baseline. (4) At screening and baseline, meets criteria for moderately severe AD based on the investigator's assessment of 3 of the following:Eczema area and severity index (EASI) score ≥12;Psoriasis Area Severity Index (IGA) score ≥3;AD involvement in ≥10% of the Body Surface Area (BSA). (5) Recent (within 1 year prior to screening) topical treatment for AD with inadequate or intolerant clinical response, as determined by the investigator\n\nExclusion Criteria:\n\n(1) Inability to swallow the test drug or refractory nausea and vomiting, malabsorption, extracorporeal biliary shunt, or the presence of a gastrointestinal disorder (e.g., Crohn's disease, ulcerative colitis, or short bowel syndrome) or other malabsorption condition that interferes with the absorption of the drug; (2) Current or history of lymphoproliferative disorders or presence of signs or symptoms suggestive of possible lymphoproliferative disorders of lymphoid tissue, including lymphadenopathy or splenomegaly; malignancies of any kind, or a history of any malignancy within the 5 years prior to Screening (except for completely resected carcinoma in situ of the cervix or non-metastatic squamous cell or basal cell carcinoma of the skin or papillary carcinoma of the thyroid gland); (3) Patients with prior thromboembolism (including deep vein thrombosis, pulmonary embolism, arterial thrombosis, etc.) or other high-risk groups prone to thromboembolism; (4) Patients with a history of herpes virus infection within the last 1 month or those with recurrent episodes of herpes zoster (≥2), disseminated herpes zoster, disseminated herpes simplex, or those for whom herpes zoster or herpes simplex infections cannot be excluded at this time;",{"count":168,"type":20},480,[23],"This clinical trial is a multicenter, randomized, double-blind, controlled phase III clinical study",[172],"Moderate to Severe Atopic Dermatitis","2025-02-07",{"date":175,"type":31},"2025-02-11",{"date":177,"type":31},"2024-12-30",{"date":119,"type":20},{"name":37,"class":38},{"id":181,"slug":182,"hasResults":11,"nctId":183,"briefTitle":184,"officialTitle":185,"acronym":4,"eligibilityCriteria":186,"healthyVolunteers":11,"sex":16,"minAge":46,"maxAge":187,"enrollmentInfo":188,"targetDuration":4,"studyType":21,"phases":190,"briefSummary":191,"conditions":192,"keywords":4,"overallStatus":112,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":195,"startDateStruct":197,"completionDateStruct":199,"leadSponsor":200,"locationsCount":39},"100560467","phase-3-efficacy-and-safety-study-of-vicagrel-in-patients-with-acute-coronary-syndrome-acs-undergoing-percutaneous-coronary-intervention-pci-100560467","NCT06577519","Efficacy and Safety Study of Vicagrel in Patients With Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI)","Efficacy and Safety of Vicagrel in Patients With With Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI): a Multi-center, Randomized, Double-blind, Double-dummy , Parallel-controlled, Phase III Trial","Inclusion Criteria:\n\n* Patients between 18 and 80 years old, with no gender restrictions.\n* Patients diagnosed with ACS and scheduled for PCI, including STEMI and NSTE-ACS (UA\u002FNSTEMI).\n* Voluntarily sign the ICF and be able to follow the visit arrangements specified in the protocol during the trial period.\n\nExclusion Criteria:\n\n* Expected survival time\\\u003C12 months;\n* Severe liver dysfunction (non heart disease induced ALT or AST\\>3x ULN) and cirrhosis;\n* Pregnant or lactating women, or participants and their partners who plan to become pregnant during the trial period;\n* The researchers determined that other reasons were not suitable for participants in this experiment.","80 Years",{"count":189,"type":20},1000,[23],"This is a multi-center, randomized, double-blind, double-dummy, parallel-controled, phase III trial, aiming to evaluate the effectiveness and safety of long-term continuous administration of Vicagrel capsules in ACS patients undergoing PCI.",[193],"Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI)","2024-09-28",{"date":196,"type":31},"2024-10-01",{"date":198,"type":31},"2024-09-06",{"date":158,"type":20},{"name":37,"class":38},""]